; and (B) section 12 of the Stevenson-Wydler Technology Innovation Act of 1980 ( 15 U.S.C. 3710a ). (2) Covered transaction The term covered transaction means any contract, funding agreement, license, other transaction, or other arrangement entered into between a party and the Federal Government on or after the date of enactment of this Act with respect to research and development regarding a drug that— (A) is intended or anticipated to be used to diagnose, mitigate, prevent, or treat COVID–19; and (B) consists of— (i) a licensing agreement pursuant to section 207 of title 35, United States Code; (ii) a cooperative research and development agreement and licensing agreement pursuant to section 12 of the Stevenson-Wydler Technology Innovation Act of 1980 ( 15 U.S.C. 3710a ); (iii) a funding agreement, as defined under section 201 of title 35, United States Code; or (iv) any other transaction entered into pursuant to— (I) section 319L, 421, or 480 of the Public Health Service Act (42 U.S.C. 247d–7e, 285b–3, 287a); (II) section 105 of the National Institutes of Health Reform Act of 2006 ( 42 U.S.C. 284n ); or (III) section 2371 of title 10, United States Code. (3) COVID–19 related invention The term COVID–19 related invention means any invention that claims a drug that is manufactured, used, designed, developed, modified, licensed, or procured to diagnose, mitigate, prevent, treat, or cure COVID–19; a use of such drug; a form of such drug; a method of use of such drug